Obsessive-Compulsive Disorder Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

The obsessive compulsive disorder pipeline market research report provides comprehensive information on the therapeutics under development for Obsessive-Compulsive Disorder, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Obsessive-Compulsive Disorder and features dormant and discontinued projects.

What are the key targets in the obsessive-compulsive disorder pipeline market?

The key targets in the obsessive-compulsive disorder pipeline market are Cannabinoid Receptor 1, Excitatory Amino Acid Transporter 2, Glutamate Ionotropic Receptor NMDA Type Subunit, 5-Hydroxytryptamine Receptor 1A, 5-Hydroxytryptamine Receptor 2A, Aromatic L Amino Acid Decarboxylase, Cannabinoid Receptor 2, Cells Expressing B Lymphocyte Antigen CD2, Glutamate Receptor Ionotropic NMDA 2B, and Phosphodiesterase 7. Cannabinoid Receptor 1 has the highest number of pipeline products in the obsessive-compulsive disorder pipeline market.

Obsessive-compulsive disorder pipeline market, by target

For more target insights, download a free report sample

What are the key MoA in the obsessive-compulsive disorder pipeline market?

The key MoA in the obsessive compulsive disorder pipeline market are Cannabinoid Receptor 1 Agonist, Excitatory Amino Acid Transporter 2 Activator, 5-Hydroxytryptamine Receptor 1A Agonist, 5-Hydroxytryptamine Receptor 2A Agonist, Aromatic L Amino Acid Decarboxylase Inhibitor, Cannabinoid Receptor 2 Agonist, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20, Glutamate Ionotropic Receptor NMDA Type Subunit Antagonist, Glutamate Receptor Ionotropic NMDA 2B Antagonist, and Phosphodiesterase 7 Inhibitor.

Obsessive-compulsive disorder pipeline market, by MoA

For more MoA insights, download a free report sample

What are the key RoA in the obsessive-compulsive disorder pipeline market?

The key RoA in the obsessive-compulsive disorder pipeline market are Oral, Intravenous, Parenteral, Subcutaneous, and Transdermal. Oral has the highest number of pipeline products in the obsessive-compulsive disorder pipeline market.

Obsessive-compulsive disorder pipeline market, by RoA

For more RoA insights, download a free report sample

What are the key molecule type in the obsessive-compulsive disorder pipeline market?

The key molecule type in the obsessive-compulsive disorder pipeline market are Small Molecule, Antibody, and Monoclonal Antibody. Small Molecule has the highest number of products in the obsessive-compulsive disorder pipeline market.

Obsessive-compulsive disorder pipeline market, by molecule type

For more molecule type insights, download a free report sample

What are the key companies in the obsessive-compulsive disorder pipeline market?

The key companies in the obsessive-compulsive disorder pipeline market are Biohaven Pharmaceutical Holding Company Ltd, Amorsa Therapeutics Inc, Biogen Inc, Cannabis Science Inc, Evecxia Therapeutics Inc, Octapharma AG, Omeros Corp, PharmaTher Holdings Ltd, Phytecs, and Rugen Therapeutics R&D (Shanghai) Co Ltd.

Obsessive-compulsive disorder pipeline market, by companies

To know more about key companies, download a free report sample

Market report overview

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Obsessive-Compulsive Disorder (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Obsessive-Compulsive Disorder (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Obsessive-Compulsive Disorder (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Obsessive-Compulsive Disorder (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Obsessive-Compulsive Disorder (Central Nervous System)

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Obsessive-Compulsive Disorder (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Obsessive-Compulsive Disorder (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.